Clinical Nurse Specialist in Salem, MA Accepting Medicare
5 Clinical Nurse Specialist nurses found. Showing 1 - 5
 Ms. Dale Karen Defort, RN CS Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Not Enrolled in Medicare Practice Location: 30 Federal St, Ste B, Salem, MA 01970 Phone: 978-740-9590 Fax: 978-744-5486 |
Mrs. Rachael Rose Blackmar, CNP PMHNP Clinical Nurse Specialist - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 81 Highland Hall, Salem, MA 01970 Phone: 978-741-2000 Fax: 978-825-6622 |
Julie Larson, RNCS Clinical Nurse Specialist - Psych/Mental Health, Child & Adolescent Medicare: Not Enrolled in Medicare Practice Location: 48 Bridge St, Salem, MA 01970 Phone: 978-744-7905 |
Dr. Judith Baldwin Boardman, PHD, RNCS Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Not Enrolled in Medicare Practice Location: 162 Federal St, 4th Floor, Salem, MA 01970 Phone: 888-682-2224 Fax: 978-745-4307 |
Mrs. Julianne Almeida, CPNP Clinical Nurse Specialist - Emergency Medicare: Not Enrolled in Medicare Practice Location: 57 Highland Ave, Salem, MA 01970 Phone: 978-354-2750 |
News Archive
Researchers compare shunts and stents to maintain blood flow in infants with heart disease
Infants with various forms of congenital heart disease require a stable source of blood flow to their lungs in order to survive until a more definitive operation can be performed. In a recent study, pediatric researchers compared two methods to provide that flow: a shunt to reroute blood and an implanted stent to maintain an open path for blood flow.
TEMPO study recommends early administration of Azilect in PD patients
Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.
Inhibiting over-production of Panx1 protein can treat melanoma
New research from Western University, Canada, has identified a potential new target for the treatment of melanoma, the deadliest of all skin cancers. Silvia Penuela and Dale Laird discovered a new channel-forming protein called Pannexin (Panx1) that is expressed in normal levels on the surface of healthy skin cells.
Treating ulcerative colitis and Crohn's disease
Ulcerative colitis and Crohn's disease are idiopathic (we don't know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract.
Newly identified risk factor for cardiovascular disease may lead to new treatments
Low levels of naturally occurring antibodies may represent an increased risk of developing cardiovascular disease, particularly stroke in men. This discovery, published in the academic journal Atherosclerosis, has now led to attempts to develop an immunization against cardiovascular disease.
› Verified 2 days ago